These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 20155995)

  • 1. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.
    Hasnain M; Vieweg WV; Fredrickson SK
    CNS Drugs; 2010 Mar; 24(3):193-206. PubMed ID: 20155995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of antipsychotic medications on appetite, weight, and insulin resistance.
    Deng C
    Endocrinol Metab Clin North Am; 2013 Sep; 42(3):545-63. PubMed ID: 24011886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimizing weight gain for patients taking antipsychotic medications: The potential role for early use of metformin.
    Hendrick V; Dasher R; Gitlin M; Parsi M
    Ann Clin Psychiatry; 2017 May; 29(2):120-124. PubMed ID: 28463344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.
    Hasnain M; Fredrickson SK; Vieweg WV
    J Psychopharmacol; 2011 Jun; 25(6):715-21. PubMed ID: 21169390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
    Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
    Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.
    Citrome L; Kalsekar I; Baker RA; Hebden T
    Curr Med Res Opin; 2014 Aug; 30(8):1629-41. PubMed ID: 24666104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight gain and glucose dysregulation with second-generation antipsychotics and antidepressants: a review for primary care physicians.
    Hasnain M; Vieweg WV; Hollett B
    Postgrad Med; 2012 Jul; 124(4):154-67. PubMed ID: 22913904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing a metformin prescribing tool for use in adults with mental illness to reduce medication-related weight gain and cardiovascular risk.
    Smith C; Myles H; Galletly C
    Australas Psychiatry; 2017 Aug; 25(4):387-390. PubMed ID: 28747113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK; Ipema HJ; Stachnik JM
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.
    Ehret M; Goethe J; Lanosa M; Coleman CI
    J Clin Psychiatry; 2010 Oct; 71(10):1286-92. PubMed ID: 20441727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should antidiabetic medicines be considered to reduce cardiometabolic risk in patients with serious mental illness?
    Mc Namara KP; Alzubaidi H; Murray M; Samorinha C; Dunbar JA; Versace VL; Castle D
    Med J Aust; 2022 Oct; 217 Suppl 7(Suppl 7):S29-S33. PubMed ID: 36183318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies.
    Bushe CJ; Bradley AJ; Doshi S; Karagianis J
    Int J Clin Pract; 2009 Dec; 63(12):1743-61. PubMed ID: 19840151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
    Newcomer JW
    CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of metformin to limit weight-gain with atypical antipsychotics.
    Lee YJ; Jeong JH
    J Clin Pharm Ther; 2011 Oct; 36(5):537-45. PubMed ID: 21418264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain.
    Grajales D; Ferreira V; Valverde ÁM
    Cells; 2019 Oct; 8(11):. PubMed ID: 31671770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review.
    Newall H; Myles N; Ward PB; Samaras K; Shiers D; Curtis J
    Int Clin Psychopharmacol; 2012 Mar; 27(2):69-75. PubMed ID: 21979790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.
    de Silva VA; Dayabandara M; Wijesundara H; Henegama T; Gunewardena H; Suraweera C; Hanwella R
    J Psychopharmacol; 2015 Dec; 29(12):1255-61. PubMed ID: 26510448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.